TTOO (T2 Biosystems) EBITDA Margin %: -488.06% (As of Sep. 2024)


TTOO T2 Biosystems Inc TTOO
12 GF Score
Price $0.00
View Full Analysis

What is T2 Biosystems EBITDA Margin %?

T2 Biosystems TTOO +25.00% 12 EBITDA Margin % is -488.06% as of Sep. 2024. GuruFocus rates TTOO with a GF Score™ of 12/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. T2 Biosystems's EBITDA for the three months ended in Sep. 2024 was $-9.69 Mil. T2 Biosystems's Revenue for the three months ended in Sep. 2024 was $1.99 Mil. Therefore, T2 Biosystems's EBITDA margin for the quarter that ended in Sep. 2024 was -488.06%.

T2 Biosystems  (OTCPK:TTOO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

T2 Biosystems EBITDA Margin % Related Terms

T2 Biosystems EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for T2 Biosystems's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

T2 Biosystems EBITDA Margin % Chart

T2 Biosystems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -576.06 -210.28 -139.38 -246.01 -609.97

T2 Biosystems Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -954.08 -542.29 -596.36 -431.51 -488.06

TTOO vs IDTA, NSTM, TMO: EBITDA Margin % Comparison

For the Diagnostics & Research subindustry, T2 Biosystems's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

T2 Biosystems EBITDA Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, T2 Biosystems's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where T2 Biosystems's EBITDA Margin % falls into.


TTOO
12GF Score
T2 Biosystems Inc TTOO
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

T2 Biosystems EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

T2 Biosystems's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-43.875/7.193
=-609.97 %

T2 Biosystems's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-9.688/1.985
=-488.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -488.06% mean?
T2 Biosystems (TTOO) has a EBITDA Margin % of -488.06% as of Sep. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on T2 Biosystems and its competitors.
Is T2 Biosystems' EBITDA Margin % too high?
T2 Biosystems' current EBITDA Margin % is -488.06%. Overall, T2 Biosystems has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does T2 Biosystems' EBITDA Margin % compare to IDTA and NSTM?
T2 Biosystems' EBITDA Margin % of -488.06% can be compared against companies in the Medical Diagnostics & Research industry. The industry median EBITDA Margin % is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on T2 Biosystems and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. T2 Biosystems's current EBITDA Margin % is -488.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is T2 Biosystems stock overvalued right now?
T2 Biosystems (TTOO) has a current EBITDA Margin % of -488.06%. The current EBITDA Margin % is -488.06%. T2 Biosystems' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For T2 Biosystems (TTOO), the current EBITDA Margin % is -488.06% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

T2 Biosystems Business Description

Address 101 Hartwell Avenue, Lexington, MA, USA, 02421
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.
12GF Score

Get the complete analysis for TTOO

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price